Discovery of Non-benzoazacyclic V 2 R Antagonists for the Treatment of Autosomal Dominant Polycystic Kidney Disease
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c02474 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Haiyang Zhong und 12 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, Jiangsu 221004, China. Hauptthemen laut MEDLINE: Polycystic Kidney, Autosomal Dominant, Antidiuretic Hormone Receptor Antagonists, Receptors, Vasopressin, Drug Discovery. Die Arbeit nennt 50 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangsu Province, National Natural Science Foundation of China, XZHMU-QL Joint Research Fund.
Abstract (Originalsprache)
Vasopressin V2 receptor (V2R) is a validated therapeutic target for autosomal dominant polycystic kidney disease (ADPKD). Most reported V2R antagonists share a benzoazacyclic scaffold with limited structural diversity. In this study, structural analysis of V2R bound to the FDA-approved V2R antagonist tolvaptan and a previously reported derivative (compound 18) revealed that the interaction with a hydrophobic subpocket formed by residues V2065.39, I2095.42, and F2876.51 plays a critical role in antagonistic activity. Guided by this structural insight, we designed a series of non-benzoazacyclic analogs. Compound 29 (XYDC2050) exhibited high V2R binding affinity (Ki = 2.8 ± 0.1 nM) and potent cAMP inhibition (IC50 = 12.0 ± 2.0 nM). Notably, XYDC2050 displayed 162-fold selectivity over V1AR, surpassing that of tolvaptan (123-fold). In vitro and in vivo studies demonstrated that XYDC2050 effectively suppressed renal cyst formation and slowed disease progression. These results support XYDC2050 as a potential lead compound for ADPKD therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, Jiangsu 221004, China.
ORCID-Profile: Haiyang Zhong, Dong Guo
Förderung
- Natural Science Foundation of Jiangsu Province
- National Natural Science Foundation of China
- XZHMU-QL Joint Research Fund
- Jiangsu Funding Program for Excellent Postdoctoral Talent
- Jiangsu Province Graduate Research and Practice Innovation Program
Zitieren
APA
Zhong, H., Zhang, Z., Chen, M., Liu, X., Zhang, Y., Zhao, W., Chen, Y., Fu, K., Yang, C., Shi, Y., Sun, Y., Liu, H., & Guo, D. (2025). Discovery of Non-benzoazacyclic V 2 R Antagonists for the Treatment of Autosomal Dominant Polycystic Kidney Disease. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02474
Vancouver
Zhong H, Zhang Z, Chen M, Liu X, Zhang Y, Zhao W, et al. Discovery of Non-benzoazacyclic V 2 R Antagonists for the Treatment of Autosomal Dominant Polycystic Kidney Disease. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c02474
BibTeX
@article{Zhong2025,
author = {Zhong, Haiyang and Zhang, Zhengshuo and Chen, Mengdan and Liu, Xuchao and Zhang, Yixiao and Zhao, Wenchao and Chen, Yue and Fu, Kequan and Yang, Can and Shi, Yuxin and Sun, Yongzhan and Liu, Hongli and Guo, Dong},
title = {Discovery of Non-benzoazacyclic V 2 R Antagonists for the Treatment of Autosomal Dominant Polycystic Kidney Disease},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c02474}
}
EUVIMED